Induction of differentiation and apoptosis in cancer cells through ligands of nuclear hormone receptors (NHRs) is a novel and promising approach to cancer therapy. All-trans-retinoic acid (ATRA), an RA receptor-specific NHR ligand, is now used for selective cancers. 
The high prevalence of breast cancer and the limited therapeutic possibilities provide a strong stimulus for identification of new, selective molecular targets for anticancer therapy. Cancers are associated with dysregulation of differentiation and apoptosis. Induction of these processes through ligands of nuclear hormone receptors (NHRs) is a recent approach to cancer therapy, particularly, in the use of RAs for treatment of acute promyelocytic leukemia (1) , early lesions of head and neck cancer (2) , squamous cell carcinoma of the cervix (3), and skin cancer (4) . The actions of retinoids are mediated by RA receptors (RARs) and retinoic X receptors (RXR) both of which are expressed in breast cancer cells. The RARs and RXRs bind to specific RA-responsive elements and regulate transcription of target genes in a ligand-dependent manner (5) (6) . Retinoids are highly effective in preventing mammary carcinogenesis in rodents (7) . The RAR-specific ligand, alltrans-RA (ATRA) selectively inhibits growth of human estrogen receptor (ER)-positive breast cancer cells (8) (9) (10) , and these cells express higher levels of RAR␣ mRNA than ERnegative lines (10) (11) . Furthermore, activation of gene transcription by RAR␣ appears to be required for inhibition of growth in human ER-positive breast cancer cells by retinoids (12) . However, inhibition of growth of breast cancer cells through retinoids is usually reversible with removal of the ligand (13) .
The peroxisome proliferator-activated receptor ␥ (PPAR␥), which also belongs to the NHR superfamily, has an important role in differentiation of adipocytes and in fat metabolism (14) (15) . Epidemiological data suggest that the incidence of breast cancer is related to consumption of a diet high in fat (16) (17) . Breast cancer cells have significant lipogenic capacity, and inhibition of fat metabolism in these cells is associated with inhibition of growth and apoptosis (18) . Recent data showed that human breast cancer cell lines as well as primary and metastatic breast adenocarcinomas expressed PPAR␥ and ligand activation of PPAR␥ caused inhibition of proliferation and extensive lipid accumulation in cultured breast cancer cell lines (19) (20) .
Various NHRs can interact with each other by suppression or activation of their target genes. For example, RXRs activated (21) and RARs suppressed the induction of PPAR␥ (22) in normal fat cells. Our previously data showed crosstalk between the NHRs; for example, ligand-activation of receptors for RAR͞RXR and vitamin D 3 resulted in a synergistic decreased proliferation and induction of apoptosis of leukemia cell lines (23) (24) . In this investigation, we analyzed the ability of a synthetic-specific ligand of PPAR␥, the antidiabetic drug troglitazone (TGZ; ref. 25) as well as several other PPAR␥ ligands either alone or in combination with ATRA to affect the growth, differentiation and apoptosis of breast cancer cells in vitro and in vivo.
Each of the diluants either alone or in combination at concentrations of 10 Ϫ5 M or less had no significant effect on breast cancer cell lines.
Clonogenic Assay in Soft Agar. Effect of NHR ligands on clonogenic growth of breast cancer cells was determined by dose-response studies in soft agar as described (26) .
Measurement of Cellular Content of Proteins and Lipid Accumulation. Expression of specific proteins was detected by Western blot, flow cytometry (24) , or by immunohistochemistry of either cytospined MCF7 cells grown in vitro or freshly fixed in formalin and embedded in paraffin (24, 26) . Western blotting, immunodetection, and stripping of membranes were performed by using standard methods (60 g of protein per lane), as recommended by the supplier of the Enhanced Chemiluminescence Detection System (Amersham). Densitometric measurements were done by using ''UVP gel analysis suite,'' Anti-PPAR␥ polyclonal antibody (516555, 1:2000, Calbiochem), anti-bcl-2 murine mAb, (clone 124, 1:50, Dako), anti-bax polyclonal antibody (N20, 1:50, Santa Cruz, CA); anti CD36 mAb (1:100, Immunotech, Luminy, France), anti-Ecadherin mAb (1:1500, Transduction Laboratories, Lexington, KY), and anti-␤-casein mAb (MAS 447 1:100, Harlan SeraLab, Sussex, England) were used. Expression of proteins in MCF7 cells stained by immunohistochemistry were measured by the total intensity score (0-300), which was calculated as the sum of the products of each intensity score (0-3) and their corresponding percentages from 300 cells. Normal IgG was substituted for specific antibody for each experiment as a negative control. Measurement of lipid accumulation was performed by staining of cells with Oil Red O (26) . Human breast adipocytes were used as positive control.
Measurement of Apoptosis. DNA strand breaks were identified by terminal deoxynucleotidyltransferase-mediated UTP end labeling (TUNEL) technique using in situ Cell Death Detection Kit, used either fluorescein or alkaline phosphatase (AP) as recommended by the supplier (Boehringer Mannheim).
Transfection of MCF7 Cells with bcl-2 Vector. MCF7 cells were transfected with a cytomegalovirus-bcl-2 expression plasmid (generous gift from J. Reed, The Burnham Institute, La Jolla, CA) or empty vector (pcDNA3) using Superfect (Qiagen). As a marker for transfection, a plasmid coding for green fluorescent protein (EGFP, CLONTECH) driven by the cyclin A1 promoter (C. Müller and H. P. Koeffler, unpublished data) was cotransfected at a ratio of 1:4. The green fluorescent protein-expressing cells were selected using a FACStar (Becton Dickinson) flow cytometric sorter.
Northern Blot Analysis. Total RNA was extracted by using Trizol (GIBCO͞BRL). Blots (30 g of total RNA) were hybridized with 32 P-labeled CCAT-Enhancer Binding Protein (5.0-kb BamHI genomic fragment), as well as aP2, lipoprotein lipase, and adipsin (cDNA). Blots were rehybridized with ␤-actin probe as control.
In Vivo Murine Cancer Model. Female triple-immunodeficient BNX nude mice (Harlan-Sprague-Dawley) at 8 weeks of age were whole body irradiated (300 rads) and 5 ϫ 10 6 of MCF7 cells in 0.1 ml of Matrigel (Collaborative Biomedical Products, Bedford, MA) were bilaterally injected s.c. into the trunk of 20 mice, forming two tumors͞mouse. Treatment was started on the day after the injection of these human breast cancer cells and finished after 9 weeks. Cohorts (5 mice͞ group) received diluant only (control group), troglitazone (1,000 mg͞kg͞day, orally by gavage), ATRA (7.5 mg͞kg͞day, i.p.), or both ligands. After 9 weeks, bloods were collected for chemistry and hematological analyses. Tumors, livers, lungs, spleens, and kidneys were fixed and stained for histological analyses. All animal experiments were in compliance with National Institutes of Health guidelines.
Statistical Analysis. All numerical data were expressed as the average of the values obtained Ϯ SD. Statistical significance of differences between tumors in mice was analyzed by nonparametric Mann-Whitney U test using STAT VIEW software (Abacus Concept, Berkeley CA). For all other experiments, significance was determined by conducting a paired Student's t test.
RESULTS
Expression of PPAR␥ Protein. Breast adenocarcinoma cells from patients ( Fig. 1 ) expressed high levels of PPAR␥ protein as seen by immunohistochemistry. In contrast, normal breast epithelial cells from individuals with breast cancer expressed low levels of PPAR␥ protein (Fig. 1) . The rank order of expression of PPAR␥ in the breast cancer cell lines was: BT474ϾMCF7ϾT47DϾMDA-MB-231, as measured by Western blot (Fig. 2) . M), washing extensively and culturing in agar, resulted in 6% and 32% decrease, respectively in clonogenic growth (Fig. 4) . Thus, growth inhibition by either TGZ or ATRA was partially reversible. In contrast, a 4-day pulse-exposure to both TGZ (10 Ϫ5 M) and ATRA (10 Ϫ6 M) irreversibly inhibited 80% clonogenic growth compared with untreated MCF7 cells (Fig.  4) . The 15d-PGJ 2 , natural ligand for PPAR␥, and indomethocin, also a PPAR␥ ligand (10 Ϫ10 -10 Ϫ5 M) inhibited clonal growth of MCF7 cells; and the rank order of inhibition was 15d-PGJ 2 ϾTGZϾindomethacin (data not shown), and this inhibition was reversible (Fig. 4) . However, the combination of ligands for PPAR␥ and RAR induced irreversible inhibition of clonal proliferation (Fig. 4) .
Effect of Ligands on Proliferation of Breast Cancer Cells in
Analysis of Apoptosis in MCF7 Cells. ATRA (10 Ϫ6 M, 4 days) did not induce apoptosis of MCF7 cells (Table 1) . TGZ (10 Ϫ5 M, 4 days) increased only slightly the percentage of apoptotic cells (13 Ϯ 8%) compared with untreated cells (8 Ϯ 3%). In contrast, the combination of both ligands significantly increased the number of MCF7 cells undergoing apoptosis (41 Ϯ 4%, P Ͻ 0.05, Table 1 ). In addition, either 15d-PGJ 2 Table 1) .
The same MCF7 cell cultures that were examined for apoptosis also were examined for apoptosis-related proteins. The TGZ did not change the level of bcl-2 protein (Fig. 5A ) compared with untreated cells. ATRA decreased the level of bcl-2 to 44% of untreated cells (P Ͻ 0.01), and the combination of both ligands decreased bcl-2 protein to nearly undetectable levels (Ͻ5% of control cells) (Fig. 5A ). In contrast, levels of bax after exposure of MCF7 cells to either TGZ alone or TGZ and ATRA changed little, and ATRA alone increased levels by Ϸ20% compared with untreated MCF7 cells (Fig. 5A ). As compared with untreated cells, levels of PPAR␥ protein in MCF7 cells slightly decreased by culturing with either TGZ (83%), ATRA (48%), or a combination of ATRA and TGZ (66%).
Effect of NHR Ligands on bcl-2-Transfected MCF7 Cells. Because the combination of TGZ and ATRA mediated both a profound decrease in bcl-2 levels and a marked increase in apoptosis, we hypothesized that the two events were linked. Therefore, the experiments were repeated in MCF7 cells transfected with bcl-2 expression vector. More than 70% of the bcl-2 transfected MCF7 cells over-expressed bcl-2 protein as measured by immunochistochemistry (data not shown), and bcl-2 protein expression was Ͼ10-fold higher in bcl-2 transfected MCF7 cells compared with MCF7 cells transfected with empty vector as measured by Western blot (Fig. 5B) . The bcl-2-transfected MCF7 breast cancer cells no longer underwent apoptosis after exposure to TGZ and ATRA; under the same conditions, those transfected with empty vector did undergo apoptosis (Table 1) . (Table 2) , and their expression of CD36 protein increased compared with untreated MCF7 cells ( Table 2 ). Exposure to ATRA alone decreased CD36 expression without a change in lipid accumulation compared with untreated cells (Table 2 ). In contrast, the combination of both ATRA (10 (Table 2) . Although TGZ induced lipid accumulation in MCF7 cells, these cells did not change their pattern of differentiation either to adipocytes as measured by expression of adipocyte-associated transcripts for C͞EBP␣, aP2, lipoprotein lipase, or adispin (data not shown), or to more differentiated breast cancer cells as measured by ␤-casein and E-cadherin (Fig. 5A) . (Figs. 6) as well as tumor weights resected at autopsy (P Ͻ 0.006) (data not shown) compared with those of diluant-treated control animals. Combination of ATRA and TGZ or ATRA alone also significantly inhibited the size (P Ͻ 0.001) (Fig. 6 ) and weights (P Ͻ 0.001) (data not shown) of the tumors. Histological analysis of MCF7 tumors from untreated mice revealed poorly differentiated infiltrating adenocarcinomas (data not shown) almost without apoptotic changes (Fig. 7A ). Mice treated with either troglitazone or ATRA showed some apoptosis as measured by morphology (data not shown) and TUNEL assay ( Fig. 7 B and  C) . However, in mice treated with the combination of both troglitazone and ATRA, almost all of the MCF7 tumor cells were either apoptotic or necrotic as measured by morphology (data not shown) or by TUNEL assay (Fig. 7D) , and extensive fibrosis of the tumors was observed (data not shown).
Effect of NHR Ligands on Expression of Lipid and
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No significant difference in either the mean weights, histology of internal organs, mean blood chemistries including liver parameters as well as hematopoietic parameters was found between diluant treated mice and those that received 9 weeks of treatment (data not shown), except for a decrease of the cholesterol level in the experimental groups that received both troglitazone and ATRA compared with the untreated mice (71 Ϯ 21 mg͞dl and 87 Ϯ 13 mg͞dl, respectively).
DISCUSSION
The PPAR␥ functions as an important regulator of lipid metabolism, and it is a key mediator of lipid storage (27) (28) . Our data show that human breast cancer cell lines and fresh breast adenocarcinomas express PPAR␥ protein, which is consistent with data from other groups (19) (20) . Furthermore, our histologic data indicated that, in contrast to breast cancer cells, the normal human breast epithelial cells lining the mammary ducts expressed a low level of PPAR␥ protein as seen in three individuals with breast cancer. Therefore, we hypothesized that prominent expression of PPAR␥ protein might be a marker for breast cancer cells; however, this hypothesis requires analysis of more normal and malignant breast tissues. In contrast to our data, another group (20) found strong positivity for PPAR␥ protein in the normal epithelial cells lining the mammary ducts from one patient. The explanation for these differences in results are unclear but may reflected distinct stages of normal mammary ducts (lactigenic or nonlactigenic period). The normal breast tissues of our patients were nonlactigenic.
Clonal growth of each of the breast cancer cell lines were inhibited by TGZ, a synthetic ligand of PPAR␥. However, the rank order of their sensitivity to TGZ was not the same as their level of PPAR␥ protein expression. The BT474 cells, which expressed the highest level of PPAR␥ protein, were relatively insensitive to the inhibitory effect of TGZ. Our data are in agreement with those from another group which showed that a breast cancer cell line with a high level of PPAR␥ protein expression had a minor response to TGZ (20) .
The ER-positive MCF7 cells were the most sensitive of the breast cancer cell lines to the reversible growth inhibitory action of TGZ; and these cells, after culture with TGZ, also had an increased accumulation of fat and an up-regulation of expression of CD36 protein, which is associated with active lipid metabolism and storage (20) (21) (22) (23) (24) (25) (26) (27) (28) (29) (30) . However, these epithelial cancer cells did not cross-differentiate to adipocytes because TGZ did not induce either increased CCAAT-enhancer binding protein ␣ expression (key transcriptional regulator of terminal adipocyte differentiation) or markers of terminal adipocyte differentiation (aP2, lipoprotein lipase, and adipsin). These data are in agreement with those from Mueller et al. 1998 (20) . In addition, our data showed that TGZ alone had no significant effect on either the levels of either PPAR␥ protein, the level of apoptosis, or the induction of differentiation as measured by expression of ␤-casein and E-cadherin.
The RAR-specific ligand, ATRA reversibly inhibited clonal growth of MCF7 cells and decreased the expression of PPAR␥ and CD36 proteins. Our data are congruent with observations from another group that showed that a RAR-specific ligand inhibited fat metabolism by suppressing induction of PPAR␥ (22) . Moreover, our studies showed that ATRA slightly increased expression of the apoptosis-related bax protein and decreased the bcl-2 protein level; however, it did not induce apoptosis of the MCF7 cells. In mark contrast, the combination of ATRA and TGZ in vitro irreversibly inhibited growth and induced prominent apoptosis of both MCF7 and fresh breast cancer cells but not normal breast epithelial cells. Also, additional ligands for PPAR␥ were examined: 15d-PGJ 2 and indomethacin (31) . Both reversibly suppressed proliferation of MCF7, and each in combination with ATRA caused an irreversible growth inhibition and mark apoptosis of MCF7 cells (Table 2 ). This effect was associated with a prominent decrease in the expression of bcl-2 and CD36 proteins, as well as a decrease of fat accumulation as compared with TGZ alone. Also, 9-cis-RA in combination with TGZ had the same effect as ATRA (data not shown). Interestingly, the combination of a RXR-specific ligand, LG10068 with TGZ did not caused either down-regulation of bcl-2 or apoptosis of MCF7 cells (data not shown), suggesting that activation of RAR may be essential for decreased level of bcl-2 protein and induction of apoptosis.
Forced over-expression of bcl-2 in MCF7 cells completely abolished cell death induced by the combination of a PPAR␥ ligand and ATRA, suggesting that their induction of apoptosis was linked to a decreased bcl-2 expression. Over-expression of bcl-2 inhibited cell death at confluence or in conditions of serum deprivation in breast cancer cells cultured with very low concentrations of fetal bovine serum (32) . Also, alterations in activation of the ER regulate bcl-2 expression in MCF7 cells (33) (34) and consequently apoptosis (35) . Our data showed that the ER-negative (MDA-MB-231) (data not shown) as well as ER-positive (MCF7) breast cancer cell lines were growth inhibited by the combination of TGZ and ATRA. Therefore, their effects may be independent of estrogen and its receptor. On the other hand, recent data suggest that the PPAR␥ ligand antagonizes the activation of the AP-1-, nuclear regulatory factor-kappa␤, and the signal transducers and activators of transcription-pathways (36-37) in monocytic cells. Likewise, the AP-1 transcriptional factor can be inhibited by ATRA in MCF7 cells (38) , and the blocking of AP-1 by ATRA may be responsible for the antitumor-promoting activity of ATRA (39) . Data have shown that blocking of AP-1 activity can be associated with the induction of apoptosis in some types of cancer cells (40) . Further studies are needed to examine the combined effect of TGZ and ATRA on the AP-1-, NFK␤-, and STAT-pathways.
Our in vivo data strongly supported our in vitro data. Histological analyses of MCF7 tumors from control mice showed typical breast adenocarcinoma. In contrast, treatment with TGZ plus ATRA markedly inhibited growth of MCF7 tumors associated with down-regulation of bcl-2 (data not shown), with striking apoptosis and fibrosis of these tumors. In fact, the residual mass was almost entirely fibrotic tissue. Mice receiving this combination did not change their weights and had no side effects as measured by extensive blood cell counts, serum chemistries including liver function tests as well as gross-autopsy and histological analyses of the major organs (data not shown). Taken together, the combination of ligands for PPAR␥ and RAR inhibited growth and induced apoptosis of breast cancer cells in vitro and in vivo; this combination may provide nontoxic and selective therapy for human breast cancers. The finding that over-expression of bcl-2 inhibited NHR ligands induced apoptosis, suggests a causal relationship between down-regulation of bcl-2 by ligands for PPAR␥ and RAR and subsequent apoptosis. 
